Scandinavian ChemoTech AB (publ)
Stockholm Stock ExchangeTotal Valuation
Scandinavian ChemoTech AB (publ) carries a market capitalization of 90.21M, placing it among publicly traded companies globally. Its enterprise value stands at 88.33M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 90.21M |
| Enterprise Value | 88.33M |
Share Statistics
Scandinavian ChemoTech AB (publ) currently has 25.45M shares outstanding.
| Shares Outstanding | 25.45M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | 7.12 |
| PB Ratio | N/A |
| P/TBV Ratio | -53.96 |
| P/FCF Ratio | -24.61 |
| P/OCF Ratio | -24.61 |
Enterprise Valuation
| EV / Sales | 7.00 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Scandinavian ChemoTech AB (publ) maintains a current ratio of 0.79, meaning it holds 0.8x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.79 |
| Quick Ratio | 0.15 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -52.18 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.48 |
Stock Price Statistics
Scandinavian ChemoTech AB (publ)'s stock has gained approximately 89.5% over the past 52 weeks. The 50-day moving average sits at 3.68, while the 200-day moving average is 4.14.
| Beta (5Y) | N/A |
| 52-Week Price Change | 89.5% |
| 50-Day Moving Average | 3.68 |
| 200-Day Moving Average | 4.14 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Scandinavian ChemoTech AB (publ) generated 12.61M in revenue and converted that into -6.31M in net income, yielding earnings per share of -0.26. EBITDA reached -5.27M, while operating income came in at -5.27M.
| Revenue | 12.61M |
| Gross Profit | 11.03M |
| Operating Income | -5.27M |
| Pretax Income | -6.31M |
| Net Income | -6.31M |
| EBITDA | -5.27M |
| EBIT | -5.27M |
| Earnings Per Share (EPS) | -0.26 |
Balance Sheet
| Cash & Cash Equivalents | 1.46M |
| Total Debt | N/A |
| Net Debt | -1.45M |
| Equity (Book Value) | N/A |
| Book Value Per Share | N/A |
| Working Capital | -1.99M |
Cash Flow
Scandinavian ChemoTech AB (publ) produced -3.65M in operating cash flow over the past twelve months.
| Operating Cash Flow | -3.65M |
| Capital Expenditures | N/A |
| Free Cash Flow | -3.65M |
| FCF Per Share | -0.15 |
Margins
Scandinavian ChemoTech AB (publ) operates with a gross margin of 87.44, reflecting its pricing power and cost economics. The operating margin of -41.83 and net profit margin of -50.01 provide insight into operational efficiency.
| Gross Margin | 87.44 |
| Operating Margin | -41.83 |
| Pretax Margin | -50.01 |
| Profit Margin | -50.01 |
| EBITDA Margin | -41.83 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -5.11 |
| FCF Yield | -4.06 |
Stock Splits
Scandinavian ChemoTech AB (publ)'s most recent stock split took place on May 30, 2024 with a 25:26 split ratio.
| Last Split Date | 5/30/2024 |
| Split Ratio | 25:26 |
Scores
Scandinavian ChemoTech AB (publ) posts an Altman Z-Score of 4.77, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 4.77 |